- Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
- Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology to Present at May and June 2024 Investor Conferences
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Sana Biotechnology Announces Pricing of Upsized Public Offering
- Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
More ▼
Key statistics
On Thursday, Sana Biotechnology Inc (SANA:NSQ) closed at 7.98, -33.50% below its 52-week high of 12.00, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.31 |
---|---|
High | 8.31 |
Low | 7.80 |
Bid | 8.00 |
Offer | 8.79 |
Previous close | 8.26 |
Average volume | 1.70m |
---|---|
Shares outstanding | 221.50m |
Free float | 202.38m |
P/E (TTM) | -- |
Market cap | 1.83bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼